Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combinat...

Por Rikke B. Holmgaard, David A. Schaer, Yanxia Li, Stephen P. Castaneda, Mary Y. Murphy, Xiaohong Xu, Ivan Inigo, Julie Dobkin, Jason R. Manro, Philip W. Iversen, David Surguladze, Gerald E. Hall, Ruslan D. Novosiadly, Karim A. Benhadji, Gregory D. Plowman, Michael Kalos, Kyla E. Driscoll
Publicado em 2018-06-01